Incyte | INCY - Umsatzkosten

Aktienkurs
99.14
Täglich Wechseln
1.40 1.43%
Monatlich
9.75%
Jährlich
58.22%
Q2 Prognose
92.62




Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Agenus USD 642K 399K 2025-09
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amgen USD 1.79B 128M 2025-12
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Exelixis USD 26.48M 7.91M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Incyte USD 121.18M 22.18M 2025-12
Ionis Pharmaceuticals USD 3M 5M 2026-03
MacroGenics USD 10.12M 34.18M 2025-12
Merck USD 3.32B 531M 2025-12
Moderna USD 452M 245M 2025-12
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novartis USD 3.54B 3M 2025-12
Novartis USD 3.54B 7M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12